ResearcherFirst Hospital of Lanzhou UniversityActive in the last 2 years
Changpeng Chai
Matched on OpenAlex author ID A5112559956. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 1 paper
Papers 5
- [Establishment and identification of organoid derived from patients with pancreatic cancer based on suspension culture]. Co-author DOI 10.3760/cma.j.cn112152-20241004-00427↗
- Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma cell line. Co-author DOI 10.1007/s13577-024-01100-y↗
- A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-56464-w↗
- Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1. Co-author DOI 10.1186/s12885-024-12588-w↗
- Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer. Co-author DOI 10.1002/jcla.24381↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wence Zhou · 4 shared papers, 2022–2024 · strength 0.75
- Paper Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer. DOI 10.1002/jcla.24381↗
- Paper A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. DOI 10.1038/s41598-024-56464-w↗
- Paper Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1. DOI 10.1186/s12885-024-12588-w↗
- Hao Xu · 3 shared papers, 2024 · strength 0.55
- Paper A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. DOI 10.1038/s41598-024-56464-w↗
- Paper Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1. DOI 10.1186/s12885-024-12588-w↗
- Paper Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma ce… DOI 10.1007/s13577-024-01100-y↗
- Huan Tang · 3 shared papers, 2024 · strength 0.55
- Paper A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. DOI 10.1038/s41598-024-56464-w↗
- Paper Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1. DOI 10.1186/s12885-024-12588-w↗
- Paper Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma ce… DOI 10.1007/s13577-024-01100-y↗
- Cheng Yu · 3 shared papers, 2024 · strength 0.55
- Paper A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma. DOI 10.1038/s41598-024-56464-w↗
- Paper Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1. DOI 10.1186/s12885-024-12588-w↗
- Paper Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma ce… DOI 10.1007/s13577-024-01100-y↗
- Canqing Yu · 1 shared paper, 2025 · strength 0.28
- Huijun Xu · 1 shared paper, 2025 · strength 0.28
- Huaqing Shi · 1 shared paper, 2022 · strength 0.20
- Hao Ming Xu · 1 shared paper, 2022 · strength 0.20
- Bo Zhang · 1 shared paper, 2024 · strength 0.18
- Zhengfeng Wang · 1 shared paper, 2024 · strength 0.18
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.